Trial Update November 12, 2026

Liraglutide Trial on Surgical Patients Marked Completed

A clinical trial involving liraglutide has been updated to completed status as of November 12, 2026. The study, registered as NCT07932119, is titled "GLP-1 Receptor Agonists in the Surgical Patient: Prevalence, Epidemiology, and Pulmonary Complications." No phase was specified for this trial in the registry listing. The trial status update indicates that the study has concluded its data collection or active research activities. No results have been reported as part of this status change, and no outcome data is included in this update. Liraglutide remains an approved compound, and this trial update reflects only a change in study status, not any findings regarding safety or efficacy. The trial appears to examine GLP-1 receptor agonists broadly in surgical patient populations, with a focus on prevalence, epidemiology, and pulmonary complications as described in the title. Readers interested in additional detail can consult the official registry entry for further information on trial design and scope. For more background on liraglutide, including its regulatory status and general profile, readers can refer to the compound overview.

See the full liraglutide overview

Source: https://clinicaltrials.gov/study/NCT07932119